Beta
Dapagliflozin
medicationSGLT2 inhibitor (brand name: Farxiga) for type 2 diabetes and heart failure. May have longevity and metabolic benefits.
Reported Benefits
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Not specified in available data
This ongoing trial in obese non-diabetic adults aged 18-40 tests dapagliflozin 10 mg for 32 weeks versus placebo and metformin, monitoring weight loss, metabolic parameters, and adverse events like dehydration risks.
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Patients With T2DM
Not specified in available data
Phase 2b/3 trials referenced show dapagliflozin 10 mg raises HDL cholesterol by about 4 mg/dL in subjects, suggesting potential HDL function improvement alongside weight reduction, though primary focus was T2DM patients.
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Patients With T2DM
Not specified in available data
Phase 2b/3 trials referenced show dapagliflozin 10 mg raises HDL cholesterol by about 4 mg/dL in subjects, suggesting potential HDL function improvement alongside weight reduction, though primary focus was T2DM patients.
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Not specified in available data
This ongoing trial in obese non-diabetic adults aged 18-40 tests dapagliflozin 10 mg for 32 weeks versus placebo and metformin, monitoring weight loss, metabolic parameters, and adverse events like dehydration risks.
Reported Side Effects
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Not specified in available data
This ongoing trial in obese non-diabetic adults aged 18-40 tests dapagliflozin 10 mg for 32 weeks versus placebo and metformin, monitoring weight loss, metabolic parameters, and adverse events like dehydration risks.
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Not specified in available data
This ongoing trial in obese non-diabetic adults aged 18-40 tests dapagliflozin 10 mg for 32 weeks versus placebo and metformin, monitoring weight loss, metabolic parameters, and adverse events like dehydration risks.
Research (2 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!